• Clin Otolaryngol · Apr 2017

    Comparative Study

    Transoral laser microsurgery versus radiation therapy in the management of T1 and T2 laryngeal glottic carcinoma: which modality is cost-effective within the UK?

    • M Prettyjohns, S Winter, C Kerawala, V Paleri, and the NICE cancer of the upper aerodigestive tract guideline committee.
    • National Collaborating Centre for Cancer, Cardiff, UK.
    • Clin Otolaryngol. 2017 Apr 1; 42 (2): 404-415.

    ObjectivesTo identify the most cost-effective treatment strategy in patients with early stage (T1 and T2) cancers of the laryngeal glottis.DesignA Markov decision model populated using data from updated systematic reviews and meta-analyses, with attributable costs from NHS sources. Data on local control and mortality were obtained from updates of existing systematic reviews conducted for the NICE guideline on cancer of the upper aerodigestive tract. Procedure costs were sourced from NHS reference costs 2013/14 by applying tariffs associated with the appropriate health resource group code SETTING: The UK National Health Service.PopulationPatients with early stage (T1 and T2) cancers of the laryngeal glottis.InterventionsTransoral laser microsurgery (TLM) and radiation therapy (RT).Main Outcome MeasuresTotal costs, incremental costs and quality adjusted life years (QALYs) over a 10-year time horizon.ResultsRadiation therapy as the initial treatment strategy was found to be more expensive (£2654 versus £623) and less effective (QALY reduction of 0.141 and 0.04 in T1a and T1b-T2 laryngeal cancers, respectively) than TLM. The dominance of TLM for T1a cancers was unchanged in most scenarios modelled in sensitivity analysis. For T1b-T2 laryngeal cancers, the result changed in numerous scenarios. In probabilistic sensitivity analysis, TLM was found to have a 71% and 58% probability of being cost-effective in T1a and T1b-T2 laryngeal cancers, respectively.ConclusionsTransoral laser microsurgery is a cost-effective strategy to adopt in the management of T1a laryngeal cancers. Uncertainty remains over the optimal strategy to adopt in T1b-T2 laryngeal cancers.© 2017 John Wiley & Sons Ltd.

      Pubmed     Full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        

    hide…

Want more great medical articles?

Keep up to date with a free trial of metajournal, personalized for your practice.
1,694,794 articles already indexed!

We guarantee your privacy. Your email address will not be shared.